Format

Send to

Choose Destination
Expert Opin Investig Drugs. 2008 May;17(5):795-804. doi: 10.1517/13543784.17.5.795 .

Betahistine: what's new on the agenda?

Author information

1
CSO-Obecure Ltd, Paz Towers, 5 Shoham St, Ramat Gan, 52121, Israel. nirbarak@post.tau.ac.il

Abstract

BACKGROUND:

Betahistine is an orally administered, centrally acting histamine H(1) receptor agonist with partial H(3) antagonistic activity and no H(2)-binding effects. In the past betahistine was clinically studied mainly as a vasodilator for conditions such as cluster headaches, vascular dementia and Meniere's disease, for which it is still used. In recent years, histamine was found to be a key neurotransmitter in the regulation of feeding behavior.

OBJECTIVE:

To provide a review of the developmental history and current research interests of betahistine.

METHODS:

All reports of betahistine use in animals and humans were retrieved and reviewed.

RESULTS/CONCLUSION:

The unique pharmacologic properties of betahistine point to its potential future use as an antiobesity agent.

PMID:
18447604
DOI:
10.1517/13543784.17.5.795
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center